Health

T-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal Cancer

TribeNews
By TribeNews Add a Comment
0 Min Read
T-DXd Prevails in Trial of Second-Line Therapies for HER2 Gastroesophageal Cancer

MedPage Today) — CHICAGO — Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) instead of ramucirumab…

Leave a Comment
Ads Blocker Image Powered by Code Help Pro

Ads Blocker Detected & This Is Prohibited!!!

We have detected that you are using extensions to block ads and you are also not using our official app. Your Account Have been Flagged and reported, pending de-activation & All your earning will be wiped out. Please turn off the software to continue

You cannot copy content of this app